The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of S-1 compared to modified FOLFIRINOX as second-line chemotherapy regimens after gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic cancer.
 
Gen Kimura
No Relationships to Disclose
 
Hideaki Takahashi
Honoraria - Taiho Pharmaceutical
Research Funding - Bayer; Bristol-Myers Squibb Japan
 
Kumiko Umemoto
No Relationships to Disclose
 
Kazuo Watanabe
No Relationships to Disclose
 
Mitsuhito Sasaki
No Relationships to Disclose
 
Yusuke Hashimoto
Research Funding - Otsuka; Taiho Pharmaceutical
 
Hiroshi Imaoka
Honoraria - Taiho Pharmaceutical
 
Izumi Ohno
No Relationships to Disclose
 
Shuichi Mitsunaga
Research Funding - ASLAN Pharmaceuticals; Bayer Holding; Chugai Pharma; Merck Serono
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kowa; Lilly Japan; Nippon Kayaku; Novartis Pharmaceuticals UK Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca; Baxter; Bayer Yakuhin; Boehringer Ingelheim; Eisai; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical